Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07085572 (Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer), which is not on this map. Cited by 135 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer
Who cites it
135 citing papers in PubMed, 6 syntheses or guidelines pooled it, 200 citations in OpenAlex.
- Meta-analysis of the association between CTCs and survival outcomes in urothelial carcinoma.BMC urology · 2026Pooled it
- SEOM-SOGUG clinical guideline for urothelial cancer (2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Guideline
- Real-world avelumab first-line maintenance in advanced urothelial carcinoma: systematic review and meta-analysis.Future oncology (London, England) · 2025Pooled it
- Role of tumor mutational burden in patients with urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Meta-analysis of platinum chemotherapy combinations with immunotherapy in metastatic urothelial carcinoma.The oncologist · 2024Pooled it
- Switch Maintenance Therapy for Metastatic Urothelial Carcinoma.Bladder cancer (Amsterdam, Netherlands) · 2022Pooled it
- Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing Schedules.Clinical genitourinary cancer · 2026Trial
- Trial
- Trial
- Pemetrexed Maintenance versus Observation in Patients with Advanced Urothelial Carcinoma Who Completed First-Line Platinum-Based Chemotherapy without Disease Progression (PREMIER, KCSG GU16-05).Cancer research and treatment · 2025Trial
- Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial.ESMO open · 2024Trial
- First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study.Cancer research communications · 2024Trial
- Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Trial
- Avelumab first-line maintenance in advanced urothelial carcinoma: Complete screening for prognostic and predictive factors using machine learning in the JAVELIN Bladder 100 phase 3 trial.Cancer medicine · 2024Trial
- Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Early versus deferred immunotherapy in urothelial carcinoma: a review of evidence and post-progression survival.International urology and nephrology · 2026Review
- Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Real-World Results From an Early Access Program in Malaysia.Asia-Pacific journal of clinical oncology · 2026Article
- Real-World Outcomes of Second-Line Chemotherapy in Metastatic Urothelial Carcinoma.Current oncology (Toronto, Ont.) · 2026Observational
- Evaluation of Drug-Drug Interactions Using Drug-PIN® in Patients Receiving Avelumab Maintenance for Advanced Urothelial Carcinoma: Evidence from the MALVA Study (Meet-URO 25).Oncology and therapy · 2026Article
75 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 14 institutions in 10 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.